Samil Pharm Total Assets
Samil Pharm total assets. Based on the latest financial reports, Samil Pharm (000520) holds total assets worth ₩375.58 Billion KRW (≈ $254.52 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Samil Pharm for the company's overall valuation and market capitalisation.
Total Assets of Samil Pharm (2011–2024)
Total assets of Samil Pharm from 2011 to 2024. This chart illustrates how Samil Pharm's total assets have evolved over time, based on quarterly financial data. See latest Samil Pharm stock price today for real-time trading data and today's change.
Samil Pharm - Asset Composition Analysis
Samil Pharm Total Assets Breakdown (December 2024)
Samil Pharm total assets breakdown as of December 2024. Samil Pharm's total assets of ₩375.58 Billion consist of 23.1% current assets and 76.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.3% |
| Accounts Receivable | ₩35.02 Billion | 8.9% |
| Inventory | ₩34.77 Billion | 8.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.51 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Samil Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Samil Pharm to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samil Pharm's current assets represent 23.1% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2024, down from 3.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 8.9% of total assets.
Samil Pharm Competitors by Total Assets
Key competitors of Samil Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Samil Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 0.74 | 1.05 |
| Quick Ratio | 0.37 | 0.47 | 0.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-51.21 Billion | ₩-29.59 Billion | ₩3.45 Billion |
Samil Pharm - Advanced Valuation Insights
This section examines the relationship between Samil Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.6% |
| Total Assets | ₩395.07 Billion |
| Market Capitalization | $105.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Samil Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Samil Pharm's assets grew by 6.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Samil Pharm (2011–2024)
The table below shows the annual total assets of Samil Pharm from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩395.07 Billion ≈ $267.73 Million |
+6.58% |
| 2023-12-31 | ₩370.68 Billion ≈ $251.20 Million |
+3.92% |
| 2022-12-31 | ₩356.70 Billion ≈ $241.73 Million |
+57.55% |
| 2021-12-31 | ₩226.40 Billion ≈ $153.43 Million |
+18.13% |
| 2020-12-31 | ₩191.66 Billion ≈ $129.89 Million |
+4.23% |
| 2019-12-31 | ₩183.87 Billion ≈ $124.61 Million |
+24.28% |
| 2018-12-31 | ₩147.95 Billion ≈ $100.26 Million |
+9.21% |
| 2017-12-31 | ₩135.48 Billion ≈ $91.81 Million |
+34.14% |
| 2016-12-31 | ₩101.00 Billion ≈ $68.44 Million |
+1.70% |
| 2015-12-31 | ₩99.31 Billion ≈ $67.30 Million |
-8.29% |
| 2014-12-31 | ₩108.29 Billion ≈ $73.39 Million |
-6.41% |
| 2013-12-31 | ₩115.71 Billion ≈ $78.41 Million |
+4.25% |
| 2012-12-31 | ₩111.00 Billion ≈ $75.22 Million |
-8.42% |
| 2011-12-31 | ₩121.20 Billion ≈ $82.14 Million |
-- |
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more